Literature DB >> 1473437

Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis.

M Campieri1, C Corbelli, P Gionchetti, C Brignola, A Belluzzi, G Di Febo, P Zagni, G Brunetti, M Miglioli, L Barbara.   

Abstract

Rectal treatment with enemas, foams, and suppositories is the most efficient method of delivering an adequate quantity of locally active drugs to the distal colon. In a pilot study carried out by colonoscopy in four patients, it was observed that 4 g 5-ASA in 20 ml foam spread up or beyond the splenic flexure and more extensively than 2 g 5-ASA in 10 ml foam. Therefore we have undertaken a study in order to compare by scintigraphy the colonic distribution of 4 g 5-ASA foam versus 4 g 5-ASA in 100 ml liquid enemas in 10 patients with ulcerative colitis using a crossover randomized design. Both preparations were labeled with 100 MBq [99mTc]sulfur colloid before administration. Anterior scans were taken at intervals for 4 hr. Activity, expressed as a percentage of total radioactivity, was measured in the rectum, sigmoid, descending, transverse, and ascending colon. Six patients had the same extent of spread with the two formulations; in three patients with foam and in one patient with enema a greater spread was observed. The foam reached the upper limit of disease in all cases, while enema failed in two cases. The maximum spread with foam was observed within 30 min in nine of 10 patients compared with seven of 10 after enema. Compared to enema, foam distributes more uniformly and seems to persist longer in the descending and sigmoid colon. The 5-ASA colonic foam shows some more favorable characteristics than enema for the local treatment of left-sided ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1473437     DOI: 10.1007/bf01308084

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Experience with short and long term courses of local adrenal steroid therapy for ulcerative colitis. Report of 98 cases.

Authors:  J A SPENCER; J B KIRSNER
Journal:  Gastroenterology       Date:  1962-06       Impact factor: 22.682

2.  Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas.

Authors:  K W Somerville; M J Langman; S P Kane; A J MacGilchrist; G Watkinson; P Salmon
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-28

3.  Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis.

Authors:  M Campieri; G A Lanfranchi; C Brignola; G Bazzocchi; P Gionchetti; M R Minguzzi; I P Cappello; C Corbelli; S Boschi
Journal:  Dis Colon Rectum       Date:  1986-02       Impact factor: 4.585

4.  Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

Authors:  M Campieri; G A Lanfranchi; G Bazzocchi; C Brignola; F Sarti; G Franzin; A Battocchia; G Labo; P R Dal Monte
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

5.  Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories.

Authors:  C N Williams; G Haber; J A Aquino
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

6.  Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis.

Authors:  R A Vitti; F Meyers; L C Knight; J A Siegel; L S Malmud; R S Fisher
Journal:  Dig Dis Sci       Date:  1989-11       Impact factor: 3.199

7.  Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21-phosphate as a retention enema.

Authors:  D A Lee; G M Taylor; V H James; G Walker
Journal:  Gut       Date:  1979-05       Impact factor: 23.059

Review 8.  5-ASA enema therapy.

Authors:  S B Hanauer
Journal:  Neth J Med       Date:  1989-06       Impact factor: 1.422

9.  Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.

Authors:  M Campieri; G A Lanfranchi; S Boschi; C Brignola; G Bazzocchi; P Gionchetti; M R Minguzzi; A Belluzzi; G Labò
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

10.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.

Authors:  L R Sutherland; F Martin; S Greer; M Robinson; N Greenberger; F Saibil; T Martin; J Sparr; E Prokipchuk; L Borgen
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

View more
  18 in total

1.  Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.

Authors:  Javier P Gisbert; María Chaparro; Fernando Gomollón
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

Review 2.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

3.  Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

Authors:  Javier P Gisbert; Fernando Gomollón; José Maté; José María Pajares
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

Review 4.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

5.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

Review 6.  [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].

Authors:  U Klotz
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 7.  Clinical pharmacokinetics of slow release mesalazine.

Authors:  M De Vos
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

8.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.

Authors:  J K Marshall; E J Irvine
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

Review 9.  Comparative tolerability of treatments for inflammatory bowel disease.

Authors:  R B Stein; S B Hanauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

10.  Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema.

Authors:  M Campieri; P Paoluzi; G D'Albasio; G Brunetti; A Pera; L Barbara
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.